High prevalence of combined thrombophilic abnormalities in patients with inflammatory bowel disease

European Journal of Gastroenterology and Hepatology

Volumn 15, Issue 11, 2003, Pages 1157-1163

  Magro, Fernando ^a,b   Dinis Ribeiro, Mario ^a   Araújo, Fernando M ^a   Pereira, Pedro ^a   Fraga, Manuela C ^a   Cunha Ribeiro, Luis M ^a   Tomé Ribeiro, António ^a  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b NONE   (Portugal)

Author keywords

Combined thrombophilic defects; Inflammatory bowel disease; Thrombosis

Indexed keywords

PROTHROMBIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD DONOR; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PORTUGAL; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOPHILIA; THROMBOSIS; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; FACTOR V; FEMALE; GENE FREQUENCY; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROTHROMBIN; STATISTICS, NONPARAMETRIC; THROMBOPHILIA;

EID: 0842265263     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200311000-00002     Document Type: Article

References (41)

1. Hudson M, Chitolie A, Hutton RA, Smith MS, Pounder RE, Wakefield AJ. Thrombotic vascular risk factors in inflammatory bowel disease. Gut 1996; 38:733-737.
2. Graef V, Baggenstoss AH, Seaur WG. Venous thrombosis occurring in non-specific ulcerative colitis. Arch Intern Med 1966; 117:377-382.
3. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia. Pathogenesis, clinical syndromes and management. Blood 1996; 87: 353-344.
4. Bovill GE, Hasstedt SJ, Leppert MF, Long GL. Hereditary thrombophilia as a model multigenic disease. Thromb Haemost 1999; 82:662-666.
5. Bertina RM, Koeleman RPC, Koster T, Rosendaal FR, Dirven RJ, Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67.
6. Seligsohn U, Zivelin A. Thrombophilia as multigenetic disorder. Thromb Haemost 1997; 78:297-301.
7. Poort SR, Rosendaal FP, Reitasma PH, Bertina RM. A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698-3703.
8. Aznar J, Estelles A, Tormo G, Sapena P, Tormo V, Blanch S, Espana F. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 1988; 59:535-541.
9. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359:641-644.
10. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism. Thromb Haemost 2001; 86:809-816.
11. De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341:801-806.
12. Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, et al. A simple classification of Crohn's disease: report of the working party for the World Congress of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000; 6:8-15.
13. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancer 1980; 1:514-515.
14. Truelove SC, Wilts LJ. Cortisone in ulcerative colitis. Br Med J 1995; ii:1041-1044.
15. Araujo F, Lopes M, Goncalves L, Maciel MJ, Cunha-Ribeiro LM. Hyperhomocysteinemia, MTHFR C677T genotype and low folate levels: a risk combination for acute coronary disease in a Portuguese population. Thromb Haemost 2000; 83:517-518.
16. Bernstein CN, Blanchard JF, Houstan DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001; 85:430-434.
17. Koutroubakis EI. Unraveling the mechanisms of thrombosis in inflammatory bowel disease. Am J Gastroenterol 2001; 91:1325-1327.
18. Wakefield AJ, Sawyerr AM, Dhillon AP, Pittilo RM, Rowles PM, Lewis AA, Pounder RE. Pathogenesis of Crohn's disease. Lancet 1989; ii: 1057-1062.
19. Wakefield AJ, Sankey EA, Dhillon AP, Sawyerr AM, More L, Sim R, et al. Granulomatous vasculitis in Crohn's disease. Gastroenterology 1991; 100:1279-1287.
20. Thompson NP, Wakefield AJ, Pounder ER. Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology 1995; 108:1011-1015.
21. Koutroubakis IE, Sfiridaki A, Mouzas IA, Maladaki A, Kapsoritakis A, Roussomoustakaki M, et al. Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. Am J Gastroenterol 2000; 95:190-194.
22. Aadland E, Odegaard OR, Roseth A, Try K. Free protein S deficiency in patients with chronic inflammatory bowel disease. Scand J Gastroenterol 1992; 27:957-960.
23. Aadland E, Odegaard OR, Roseth A, Try K. Free protein S deficiency in patients with Crohn's disease. Scand J Gastroenterol 1994; 29: 333-335.
24. Chamouard P, Grunebaum L, Wiesel ML, Freyssinet JM, Duclos B, Cazenave JP, Baumann R. Prevalence and significance of anticardiolipin antibodies in Crohn's disease. Dig Dis Sci 1994; 39:1501-1504.
25. Aichbichler BW, Petritsch W, Reicht GA, Wenzl HH, Eherer AJ, Hinterleitner TA, et al. Anticardiolipin antibodies in patients with inflammatory bowel disease. Dig Dis Sci 1999; 44:852-856.
26. Koutroubakis IE, Petinaki E, Anagnostopoulou E, Kritikos H, Mouzas IA, Kouroumalis EA, Manousos ON. Anticardiolipin and anti β2 glycoprotein I antibodies in patients with inflammatory bowel disease. Dig Dis Sci 1998; 43:2507-2512.
27. Jackson LM, O'Gorman PJ, O'Connell J, Cronin CC, Cotter KP, Shanahan F. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. Quart J Med 1997; 90: 183-188.
28. Souto JC, Martinez E, Roca M, Mateo J, Pujol J, Gonzalez D, Fontcuberta J. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995; 40: 1883-1889.
29. Souto JC, Borrel M, Fontcuberta J, Roca M. Antiphospholipid antibodies in inflammatory bowel disease. Dig Dis Sci 1995; 40:1524-1525.
30. Guedon C, Le Cam-Duchez V, Lalaude O, Menard JF, Lerebours E, Borg JY. Prothrombotic inherited abnormalities other than factor V Leiden mutation do not play a role in venous thrombosis in inflammatory bowel disease. Am J Gastroenterol 2001; 96:1448-1454.
31. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346:1133-1134.
32. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85:1504-1508.
33. Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CR. The prothrombotic gene G20210A variant prevalence in a U.K. anticoagulant clinic population. Br J Haematol 1997; 98:353-355.
34. Castellino FJ. Biochemistry of human plasminogen. Semin Thromb Haemostas 1984; 10:18-23.
35. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to IL-1 in HEP G2 cells. J Biol Chem 1993; 268:10739-10745.
36. Daemen MJAP, Lombardi DM, Bosman FT, Schwartz FM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991; 68:450-456.
37. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992; 51:197-205.
38. Liebman HA, Kashani N, Sutherland D, McGehee W, Kam AL. The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease. Gastroenterology 1998; 115:830-834.
39. Novacek G, Miehsler W, Kapiotis S, Katzenschlager R, Speiser W, Vogelsang H. Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease. Am J Gastroenterol 1999; 94:685-690.
40. de Jong E, Porte RJ, Knot EA, Verheijen JH, Dees J. Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces. Gut 1989; 30:188-194.
41. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84:1031-1035.